title: Lixisenatide as add-on treatment among patients with different β-cell function levels as assessed by HOMA-β index.
abstract: The effect of lixisenatide-a prandial once-daily glucagon-like peptide-1 receptor agonist-on glycaemic control in patients with inadequately controlled type 2 diabetes mellitus (T2DM), stratified by baseline β-cell function, was assessed.
  
  
  
  The 24-week GetGoal-M, -P and -S trials evaluated the efficacy and safety of lixisenatide in combination with oral antidiabetic agents. This post hoc analysis used data from patients receiving lixisenatide in these trials, divided into matched cohorts by propensity scoring, and stratified according to baseline homeostasis model assessment of β-cell function (HOMA-β) index levels, high HOMA-β: > median HOMA-β (28.49%); low HOMA-β: ≤ median.
  
  
  
  The matched "low" and "high" HOMA-β index cohorts (N = 546 patients) had comparable baseline parameters. Mean change from baseline in glycated haemoglobin (HbA1c) was -0.85% and -0.94% for low and high HOMA-β cohorts, respectively (P = .2607). Reductions from baseline in fasting plasma glucose (FPG; -0.77 vs -1.04 mmol/L; P = .1496) and postprandial plasma glucose (PPG; -5.82 vs -5.61 mmol/L; P = .7511) were similar in the low versus high HOMA-β index cohorts. Reduction in body weight was significantly greater in the low versus high HOMA-β index cohort (-2.06 vs -1.13 kg, respectively; P = .0006).
  
  
  
  In patients with T2DM, lixisenatide was associated with reduction in HbA1cand improvements in both FPG and PPG, regardless of β-cell function, indicating that lixisenatide is effective in reducing hyperglycaemia, even in patients with more advanced stages of T2DM and poor residual β-cell function.
authors.affiliation: University of Parma and Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.
authors.forename: Riccardo C
authors.identifier: 0000-0002-9809-1005
authors.initials: RC
authors.lastname: Bonadonna
authors.affiliation: Frank Riddick Diabetes Institute, Department of Endocrinology, Ochsner Medical Center, New Orleans, LA, USA.
authors.forename: Lawrence
authors.initials: L
authors.lastname: Blonde
authors.affiliation: Moscow Department of Health Care, Moscow, Russian Federation.
authors.forename: Mikhail
authors.initials: M
authors.lastname: Antsiferov
authors.affiliation: Sanofi, Bridgewater, NJ, USA.
authors.forename: Rachele
authors.initials: R
authors.lastname: Berria
authors.affiliation: Diabetology Department, Toulouse University Hospital, Toulouse, France.
authors.forename: Pierre
authors.initials: P
authors.lastname: Gourdy
authors.affiliation: Department of Endocrinology, Mater Misericordiae University Hospital, Dublin, Ireland.
authors.forename: Mensud
authors.initials: M
authors.lastname: Hatunic
authors.affiliation: Madras Diabetes Research Foundation & Dr Mohan's Diabetes Specialities Centre, Chennai, India.
authors.forename: Viswanathan
authors.initials: V
authors.lastname: Mohan
authors.affiliation: Royal Adelaide Hospital, Adelaide, Australia.
authors.forename: Michael
authors.initials: M
authors.lastname: Horowitz
mesh_terms: D000328:Adult; D000368:Aged; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007333:Insulin Resistance / Q000502:physiology*; D050417:Insulin-Secreting Cells / Q000187:drug effects / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic / Q000706:statistics & numerical data; D010455:Peptides / Q000008:administration & dosage*; D010919:Placebos; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D012720:Severity of Illness Index; D000067758:Glucagon-Like Peptide-2 Receptor
chemical_list: D007004:Hypoglycemic Agents; D010455:Peptides; D010919:Placebos; C479460:lixisenatide; D000067758:Glucagon-Like Peptide-2 Receptor
keywords: HOMA-β index; lixisenatide; type 2 diabetes mellitus; β-cell function